Table 1.
Dose-volume constraints as defined in the DVH constraints prediction model.
Fig 1.
Average DVH for target volumes and organs at risk for the validation experiment for the unilateral breast for clinic A (25 cases).
The reference lines (CL) are for the original plans manually optimised, while the RapidPlan lines (KB) are for the model-based optimisation.
Fig 2.
Average DVH for target volumes and organs at risk for the validation experiment on bilateral breast for the clinic B (10 cases).
The reference lines (CL) are for the original plans manually optimised, while the RapidPlan lines (KB) are for the model-based optimisation.
Table 2.
Summary of the DVH analysis for the reference and the RapidPlan plans.
PTV data are normalised to the respective prescription doses, different for each clinic.
Table 3.
Summary of the DVH analysis for the reference and the RapidPlan plans for the bilateral breast cases.
PTV data are normalised to the respective prescription doses, different for each clinic.
Table 4.
Summary of the case-by-case pass-fail analysis for the selected dose-volume planning objectives for the reference and for the model-based plans for all the 50 validation cases for the single breast (25,15,10 from clinics A,B and C respectively).